
Capping the cost of insulin: altruistic or strategic?
The price of insulin has become one of the most talked about issues across the pharma industry.
Newsletters and Deep Dive digital magazine
The price of insulin has become one of the most talked about issues across the pharma industry.
SEL-212 will compete with Horizon's fast-growing Krystexxa if approved by the FDA.
Icahn's board picks "will damage Illumina’s core business," says the gene sequencing company.
US agency sets 23rd August deadline for palovarotene review as Ipsen files more clinical data.
Industry groups are happy with news on R&D tax credits, funding for MHRA, and investment zones.
Editor's Picks
Newsletters and Deep Dive
digital magazine